Allogene Therapeutics Inc

This proposal asks stockholders to cast a non-binding advisory vote approving the compensation paid to the Company’s named executive officers as disclosed in the proxy statement. Management is seeking this endorsement to demonstrate stockholder support for its pay philosophy, which emphasizes pay-for-performance alignment through a mix of base salary, annual performance-based cash incentives, and long-term equity (stock options, RSUs and PSUs) heavily weighted toward performance-based vehicles. The Board and Compensation Committee argue the program supports retention and aligns executives with long-term stockholder value creation, citing features such as independent consultant benchmarking, stock ownership guidelines, clawback policy, and multi-year vesting. The vote is advisory and not binding, but the Board states it will consider the result when making future compensation decisions; the company also notes prior strong stockholder support (approximately 90.77% in 2025). Key company-specific context includes the firm’s pre-commercial, clinical-stage status, its reliance on equity incentives to align long-term performance, and the reintroduction of PSUs tied to ALLO-329 milestones in 2025. Management emphasizes that most pay is “at risk” and tied to performance or stock-price appreciation, while the Compensation Committee retains discretion to structure awards to reflect market practice and investor feedback. Opposing perspectives (from investors who favor different mixes of pay or stronger performance metrics) are not presented as formal shareholder proposals here, but the advisory vote provides a vehicle for shareholders to express concerns. Given the advisory nature, analysts should evaluate the vote in context of prior say-on-pay results, actual compensation realized by executives, and how the Committee ties pay to measurable milestones and retention objectives. Overall, the proposal is a governance-level ratification of the Compensation Committee’s choices rather than a discrete operational decision, and a high level of support would indicate investor alignment with the Committee’s current approach while a low level of support would signal a need for material program adjustments.

This proposal asks stockholders to indicate, on a non-binding basis, whether they prefer an advisory say-on-pay vote every year, every two years, or every three years; management recommends the annual option. The Board argues that because executive compensation disclosures are produced annually and compensation decisions evolve year-to-year, a one-year frequency best preserves investor input and accountability. The proposal is advisory and non-binding—regardless of the outcome the Board retains discretion—but a strong vote for a particular frequency is expected to influence future Board practice. Company context: the Board adopted an annual say-on-pay policy following stockholder preference in 2020 and continues to engage with investors on compensation matters; prior say-on-pay votes have shown strong support. From a governance-analysis perspective, annual votes increase the cadence of shareholder feedback but may limit the Board’s ability to make multi-year program changes between meetings; multi-year votes reduce administrative frequency but lessen timely stockholder signaling. Analysts should weigh the company’s stage (clinical-stage, equity-heavy compensation) and history of investor outreach in assessing the relevance of annual feedback. A vote for one year signals that shareholders want continual, near-term input into compensation design, whereas a vote for longer intervals would indicate tolerance for less frequent oversight. The Board’s recommended position reflects a preference for responsive governance and continued engagement with stockholders on compensation matters.

This proposal seeks shareholder approval to amend the Company’s certificate of incorporation to increase authorized common shares from 400 million to 800 million (total authorized shares to 810 million including preferred). Management frames the change as a practical step to preserve corporate flexibility—enabling future equity financings, strategic collaborations, share issuance under equity plans, and permitting option exercises—without the delay of calling a special meeting. Company-specific context includes the current outstanding share count (345,024,351 on the record date), existing reserves for outstanding awards and plans, and a recent underwriting that issued 100,200,000 shares in April 2026; management also notes that certain executives agreed not to exercise options until this amendment is approved to avoid surpassing authorized share limits. While the immediate approval does not itself dilute existing holders, it enables potential future dilution when the board exercises its issuance authority; the filing expressly warns of possible dilutive and anti-takeover effects from large authorized-but-unissued share pools. From a governance standpoint, investors should evaluate (i) the company’s near-term capital needs and dilution plan, (ii) whether management has specific planned issuances or financings that justify the quantum of the increase, and (iii) protections such as preemptive rights (which the company does not provide) or commitments regarding how newly authorized shares will be used. The Board states it reserves discretion to abandon the amendment if it later determines it is not in stockholders’ best interests, but absent contractual limits the board would have broad authority to issue new shares. Analysts should thus weigh the company’s capital runway, pipeline milestones (e.g., ALPHA3, ALLO-329), prior financing cadence, and governance protections when assessing the risk/benefit trade-off inherent in approving this amendment. Overall, the amendment is positioned as enabling strategic optionality; the principal investor concern is potential dilution and the lack of preemptive rights or restrictive covenants limiting how the board may deploy the additional authorization.